Measurement | n* | Case or case control | Heterogeneity | Pooled rate / HR | Begg’s test ( P) | Egger’s test ( P) | |
---|---|---|---|---|---|---|---|
P | I 2(%) | (95% CI) | |||||
Recurrence-free survival | |||||||
Superficial bladder cancer | |||||||
Maintenance vs. Induction | 9 | 521/536 | 0.150 | 12.0 | 0.516 (0.425-0.627) | 0.602 | 0.353 |
Low-dose vs. Standard-dose | 7 | 998/1018 | 0.831 | 0.00 | 1.162 (1.051-1.285) | 1.000 | 0.126 |
BCG plus MMC vs. BCG | 6 | 416/563 | <0.001 | 79.1 | 0.726 (0.490-1.075) | 0.452 | 0.334 |
BCG plus MMC vs. MMC | 3 | 213/225 | 0.297 | 17.7 | 0.854 (0.663-1.099) | 0.296 | 0.132 |
BCG plus Epirubicin vs. BCG | 3 | 124/152 | 0.652 | 0.00 | 0.618 (0.384-0.993) | 1.000 | 0.538 |
BCG plus IFN-α2b vs. BCG | 2 | 383/342 | 0.621 | 0.00 | 1.075 (0.859-1.345) | 1.000 | NA |
High-risk NMIBC | |||||||
Maintenance vs. Induction | 5 | 353/362 | 0.272 | 22.4 | 0.515 (0.411-0.646) | 0.086 | 0.032 |
BCG plus MMC vs. BCG | 3 | 314/298 | <0.001 | 89.8 | 0.852 (0.449-1.617) | 1.000 | 0.689 |
BCG plus MMC vs. MMC | 2 | 123/133 | 0.119 | 58.7 | 0.797 (0.477-1.330) | 1.000 | NA |
BCG plus Epirubicin vs. BCG | 2 | 100/102 | 0.556 | 0.00 | 0.544 (0.302-0.980) | 1.000 | NA |
Progression-free survival | |||||||
Superficial bladder cancer | |||||||
Maintenance vs. Induction | 7 | 452/488 | 0.380 | 6.20 | 0.740 (0.572-0.957) | 0.764 | 0.399 |
Low-dose vs. Standard-dose | 6 | 961/981 | 0.829 | 0.00 | 1.151 (0.853-1.554) | 0.452 | 0.112 |
BCG plus MMC vs. BCG | 3 | 314/298 | 0.001 | 85.3 | 0.602 (0.181-1.999) | 1.000 | 0.420 |
BCG plus MMC vs. MMC | 3 | 213/225 | 0.827 | 0.00 | 0.927 (0.482-1.784) | 1.000 | 0.493 |
BCG plus Epirubicin vs. BCG | 2 | 100/102 | 0.980 | 0.00 | 0.513 (0.132-1.987) | 1.000 | NA |
High-risk NMIBC | |||||||
Maintenance vs. Induction | 5 | 353/362 | 0.581 | 0.00 | 0.722 (0.548-0.951) | 0.806 | 0.311 |
BCG plus MMC vs. BCG | 3 | 314/298 | 0.001 | 85.3 | 0.602 (0.181-1.999) | 1.000 | 0.420 |
BCG plus MMC vs. MMC | 2 | 123/133 | 0.813 | 0.00 | 0.829 (0.387-1.773) | 1.000 | NA |
BCG plus Epirubicin vs. BCG | 2 | 100/102 | 0.980 | 0.00 | 0.513 (0.132-1.987) | 1.000 | NA |